Ascentage Pharma Group Ltd - AAPGV Earnings growth forecast for next year
The projected growth of net income per share for year n+1 reflects expert expectations, where 7.20 becomes the new value for this metric. Ascentage Pharma Group (AAPGV) is implementing ESG standards to reduce its environmental footprint during the development of oncology drugs. Market capitalization is based on partner payments for achievements in apoptosis therapy. High demand for the treatment of resistant leukemias in the US and China ensures a steady patient inflow.
Analytical breakdowns for Ascentage Pharma Group
- price and consensus price forecast:
- issuer market value details:
- book capitalization indicators:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Ascentage Pharma Group|AAPGV - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital ascentage.com|AAPGV - Company Cumulative Debt|Debt to Book Capitalization Ratio Ascentage|AAPGV - Company Long-Term Indebtedness|Company Current Liabilities Ascentage Pharma|Quick Ratio ascentage.com
- earnings and valuation multiples information:
AAPGV - Net Profit|Projected Future Earnings Ascentage Pharma Group|AAPGV - Market Cap to Net Income Ratio|Forward P/E Multiple Ascentage|AAPGV - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Ascentage Pharma Group Ltd|AAPGV - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Ascentage Pharma|AAPGV - Earnings per one share for the last 12 months|Quarterly EPS earnings growth ascentage.com|AAPGV - Earnings per share increase in current year|Earnings growth forecast for next year Ascentage Pharma Group
- revenue and sales proceeds data:
Fundamental company analysis:AAPGV, Ascentage Pharma
The peak of innovation activity at Ascentage Pharma Group (AAPGV) and the anticipation of apoptosis inhibitor trial results directly determine the projected trajectory of future earnings per share. This metric measures the analyst consensus forecast for EPS growth rates, reflecting market confidence in pipeline commercialization, while an overly optimistic modeled EPS growth for the next fiscal year may signal an overvaluation of assets.
Competing companies
ONC (BeiGene Ltd) - Earnings growth forecast for next year|Expected net earnings per share growth next year Halozyme Therapeutics HALO|Net earnings per share growth forecast for next year Revolution Medicines, Inc. (RVMD)|Earnings growth forecast for next year Ascentage Pharma Group International (AAPG)|Earnings growth forecast for next year CGON (CG Oncology Inc)|Expected earnings per share trend next year URGN|bicara.com - Earnings growth forecast for next year|Expected earnings per share trend next year PSNL (personalis.com)|Erasca Inc (ERAS) - Net earnings per share growth forecast for next year|Expected earnings per share growth for next year Delcath Systems|YMAB (YmAbs) - Earnings growth forecast for next year|AURA: Expected earnings per share trend next year|Net earnings per share growth forecast for next year Candel Therapeutics, Inc. (CADL)|Earnings growth forecast for next year Accuray (ARAY)|Net earnings per share growth forecast for next year SELLAS Life Sciences Group Inc. SLS|Actuate Therapeutics, Inc (ACTU) - Expected net earnings per share growth next year|CTOR - Net earnings per share growth forecast for next year|HURA: Net earnings per share growth forecast for next year|TARA (Protara) - Expected earnings per share growth for next year|Fate Therapeutics, Inc. - Expected earnings per share trend next year|WHWK (aadibio.com) - Earnings growth forecast for next year|TCRX: Expected earnings per share trend next year|Net earnings per share growth forecast for next year Champions Oncology (CSBR)|XBiotech - Projected earnings per share growth rate for next year|Net earnings per share growth forecast for next year CEL-SCI CVM|Consensus forecast of earnings per share growth for next year OS Therapies (OSTX)|Radiopharm Theranostics Limited - Earnings growth forecast for next year|Expected net earnings per share growth next year Artiva Biotherapeutics|ANL (adlainortye.com) - Expected earnings per share growth for next year|Expected earnings per share growth for next year Veru Pharma|TPST (Tempest Therapeutics Inc) - Earnings growth forecast for next year|Xilio Therapeutics, Inc. (XLO) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Enochian BioSciences (RENB)|MURA: Net earnings per share change forecast for next year|Earnings growth forecast for next year KAPA (kairospharma.com)|Consensus forecast of earnings per share growth for next year OnKure (OKUR)|CytoMed Therapeutics Ltd - Earnings growth forecast for next year|curis.com (CRIS) - Expected earnings per share growth for next year|Apollomics Corp (APLM) - Net earnings per share growth forecast for next year|Tharimmune - Expected earnings per share trend next year|ADVB (Advanced Biomed Corp) - Earnings growth forecast for next year|Expected earnings per share growth for next year Genprex, Inc (GNPX)|Earnings growth forecast for next year CLDI|SBFM: Net earnings per share change forecast for next year|Earnings growth forecast for next year XBIO (xeneticbio.com)|Earnings growth forecast for next year Salarius Pharmaceuticals Inc SLRX|purple-biotech.com - Earnings growth forecast for next year|Expected net earnings per share growth next year American Oncology Network, Inc.|BGNE: Earnings growth forecast for next year|Expected earnings per share growth for next year checkpointtx.com|Net earnings per share growth forecast for next year Elevation Oncology, Inc.|iCAD, Inc. (ICAD) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Ikena (IKNA)|NTBL - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year viracta.com VIRX|morphosys.com (MOR) - Expected net earnings per share growth next year|NAYA Biosciences Inc - Earnings growth forecast for next year
